A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.

As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.

Pfizer and eFFECTOR Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.

PhoreMost entered into a multi-project drug discovery collaboration with Boehringer Ingelheim to develop innovative therapies for diseases with unsatisfactory treatments.

Companies from across the globe provide updates on their business and pipeline progress.

Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.

Seattle Genetics is looking for a quicker path to resolution with Daiichi Sankyo over antibody drug conjugate technology that both companies claim ownership of.

Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.

Evotec SE announced a strategic multi-year collaboration with Takeda Pharmaceutical Company Limited to establish at least five drug discovery programs across multiple therapeutic areas.

Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.